1 Study Coverage 1.1 Long Acting Beta Agonist Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Introduction 1.2 Global Long Acting Beta Agonist Outlook 2017 VS 2022 VS 2028 1.2.1 Global Long Acting Beta Agonist Market Size for the Year 2017-2028 1.2.2 Global Long Acting Beta Agonist Market Size for the Year 2017-2028 1.3 Long Acting Beta Agonist Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Long Acting Beta Agonist in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Long Acting Beta Agonist Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Long Acting Beta Agonist Market Dynamics 1.4.1 Long Acting Beta Agonist Industry Trends 1.4.2 Long Acting Beta Agonist Market Drivers 1.4.3 Long Acting Beta Agonist Market Challenges 1.4.4 Long Acting Beta Agonist Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Long Acting Beta Agonist by Type 2.1 Long Acting Beta Agonist Market Segment by Type 2.1.1 Liquid 2.1.2 Tablet 2.2 Global Long Acting Beta Agonist Market Size by Type (2017, 2022 & 2028) 2.3 Global Long Acting Beta Agonist Market Size by Type (2017-2028) 2.4 United States Long Acting Beta Agonist Market Size by Type (2017, 2022 & 2028) 2.5 United States Long Acting Beta Agonist Market Size by Type (2017-2028) 3 Long Acting Beta Agonist by Application 3.1 Long Acting Beta Agonist Market Segment by Application 3.1.1 Hospitals 3.1.2 Clinics 3.1.3 Ambulatory Surgical Center 3.1.4 Others 3.2 Global Long Acting Beta Agonist Market Size by Application (2017, 2022 & 2028) 3.3 Global Long Acting Beta Agonist Market Size by Application (2017-2028) 3.4 United States Long Acting Beta Agonist Market Size by Application (2017, 2022 & 2028) 3.5 United States Long Acting Beta Agonist Market Size by Application (2017-2028) 4 Global Long Acting Beta Agonist Competitor Landscape by Company 4.1 Global Long Acting Beta Agonist Market Size by Company 4.1.1 Top Global Long Acting Beta Agonist Companies Ranked by Revenue (2021) 4.1.2 Global Long Acting Beta Agonist Revenue by Player (2017-2022) 4.2 Global Long Acting Beta Agonist Concentration Ratio (CR) 4.2.1 Long Acting Beta Agonist Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Long Acting Beta Agonist in 2021 4.2.3 Global Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Long Acting Beta Agonist Headquarters, Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Type 4.3.1 Global Long Acting Beta Agonist Headquarters and Area Served 4.3.2 Global Long Acting Beta Agonist Companies Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Long Acting Beta Agonist Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Long Acting Beta Agonist Market Size by Company 4.5.1 Top Long Acting Beta Agonist Players in United States, Ranked by Revenue (2021) 4.5.2 United States Long Acting Beta Agonist Revenue by Players (2020, 2021 & 2022) 5 Global Long Acting Beta Agonist Market Size by Region 5.1 Global Long Acting Beta Agonist Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Long Acting Beta Agonist Market Size by Region (2017-2028) 5.2.1 Global Long Acting Beta Agonist Market Size by Region: 2017-2022 5.2.2 Global Long Acting Beta Agonist Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Long Acting Beta Agonist Market Size YoY Growth 2017-2028 6.1.2 North America Long Acting Beta Agonist Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Long Acting Beta Agonist Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Long Acting Beta Agonist Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Long Acting Beta Agonist Market Size YoY Growth 2017-2028 6.3.2 Europe Long Acting Beta Agonist Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Long Acting Beta Agonist Market Size YoY Growth 2017-2028 6.4.2 Latin America Long Acting Beta Agonist Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Long Acting Beta Agonist Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Long Acting Beta Agonist Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Sumitomo Dainippon Pharma 7.1.1 Sumitomo Dainippon Pharma Company Details 7.1.2 Sumitomo Dainippon Pharma Business Overview 7.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Introduction 7.1.4 Sumitomo Dainippon Pharma Revenue in Long Acting Beta Agonist Business (2017-2022) 7.1.5 Sumitomo Dainippon Pharma Recent Development 7.2 AstraZeneca 7.2.1 AstraZeneca Company Details 7.2.2 AstraZeneca Business Overview 7.2.3 AstraZeneca Long Acting Beta Agonist Introduction 7.2.4 AstraZeneca Revenue in Long Acting Beta Agonist Business (2017-2022) 7.2.5 AstraZeneca Recent Development 7.3 GlaxoSmithKline 7.3.1 GlaxoSmithKline Company Details 7.3.2 GlaxoSmithKline Business Overview 7.3.3 GlaxoSmithKline Long Acting Beta Agonist Introduction 7.3.4 GlaxoSmithKline Revenue in Long Acting Beta Agonist Business (2017-2022) 7.3.5 GlaxoSmithKline Recent Development 7.4 Boehringer Ingelheim International 7.4.1 Boehringer Ingelheim International Company Details 7.4.2 Boehringer Ingelheim International Business Overview 7.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Introduction 7.4.4 Boehringer Ingelheim International Revenue in Long Acting Beta Agonist Business (2017-2022) 7.4.5 Boehringer Ingelheim International Recent Development 7.5 Mylan 7.5.1 Mylan Company Details 7.5.2 Mylan Business Overview 7.5.3 Mylan Long Acting Beta Agonist Introduction 7.5.4 Mylan Revenue in Long Acting Beta Agonist Business (2017-2022) 7.5.5 Mylan Recent Development 7.6 Teva 7.6.1 Teva Company Details 7.6.2 Teva Business Overview 7.6.3 Teva Long Acting Beta Agonist Introduction 7.6.4 Teva Revenue in Long Acting Beta Agonist Business (2017-2022) 7.6.5 Teva Recent Development 7.7 Merck 7.7.1 Merck Company Details 7.7.2 Merck Business Overview 7.7.3 Merck Long Acting Beta Agonist Introduction 7.7.4 Merck Revenue in Long Acting Beta Agonist Business (2017-2022) 7.7.5 Merck Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Long Acting Beta Agonist Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Long Acting Beta Agonist Market Trends Table 3. Long Acting Beta Agonist Market Drivers Table 4. Long Acting Beta Agonist Market Challenges Table 5. Long Acting Beta Agonist Market Restraints Table 6. Global Long Acting Beta Agonist Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Long Acting Beta Agonist Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Long Acting Beta Agonist Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Long Acting Beta Agonist Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Long Acting Beta Agonist Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Long Acting Beta Agonist Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Long Acting Beta Agonist Revenue Share by Player, 2017-2022 Table 13. Global Long Acting Beta Agonist Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Long Acting Beta Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Acting Beta Agonist as of 2021) Table 15. Top Players of Long Acting Beta Agonist in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Long Acting Beta Agonist Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Long Acting Beta Agonist Players in United States Market, Ranking by Revenue (2021) Table 20. United States Long Acting Beta Agonist Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Long Acting Beta Agonist Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Long Acting Beta Agonist Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Long Acting Beta Agonist Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Long Acting Beta Agonist Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Long Acting Beta Agonist Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Long Acting Beta Agonist Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Long Acting Beta Agonist Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Long Acting Beta Agonist Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Long Acting Beta Agonist Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Sumitomo Dainippon Pharma Company Details Table 31. Sumitomo Dainippon Pharma Business Overview Table 32. Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Table 33. Sumitomo Dainippon Pharma Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 34. Sumitomo Dainippon Pharma Recent Development Table 35. AstraZeneca Company Details Table 36. AstraZeneca Business Overview Table 37. AstraZeneca Long Acting Beta Agonist Product Table 38. AstraZeneca Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 39. AstraZeneca Recent Development Table 40. GlaxoSmithKline Company Details Table 41. GlaxoSmithKline Business Overview Table 42. GlaxoSmithKline Long Acting Beta Agonist Product Table 43. GlaxoSmithKline Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 44. GlaxoSmithKline Recent Development Table 45. Boehringer Ingelheim International Company Details Table 46. Boehringer Ingelheim International Business Overview Table 47. Boehringer Ingelheim International Long Acting Beta Agonist Product Table 48. Boehringer Ingelheim International Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 49. Boehringer Ingelheim International Recent Development Table 50. Mylan Company Details Table 51. Mylan Business Overview Table 52. Mylan Long Acting Beta Agonist Product Table 53. Mylan Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 54. Mylan Recent Development Table 55. Teva Company Details Table 56. Teva Business Overview Table 57. Teva Long Acting Beta Agonist Product Table 58. Teva Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 59. Teva Recent Development Table 60. Merck Company Details Table 61. Merck Business Overview Table 62. Merck Long Acting Beta Agonist Product Table 63. Merck Revenue in Long Acting Beta Agonist Business (2017-2022) & (US$ Million) Table 64. Merck Recent Development Table 65. Research Programs/Design for This Report Table 66. Key Data Information from Secondary Sources Table 67. Key Data Information from Primary Sources List of Figures Figure 1. Long Acting Beta Agonist Product Picture Figure 2. Global Long Acting Beta Agonist Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Long Acting Beta Agonist Market Size 2017-2028 (US$ Million) Figure 4. United States Long Acting Beta Agonist Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Long Acting Beta Agonist Market Size 2017-2028 (US$ Million) Figure 6. United States Long Acting Beta Agonist Market Share in Global 2017-2028 Figure 7. Long Acting Beta Agonist Report Years Considered Figure 8. Product Picture of Liquid Figure 9. Product Picture of Tablet Figure 10. Global Long Acting Beta Agonist Market Share by Type in 2022 & 2028 Figure 11. Global Long Acting Beta Agonist Market Size by Type (2017-2028) & (US$ Million) Figure 12. Global Long Acting Beta Agonist Market Share by Type (2017-2028) Figure 13. United States Long Acting Beta Agonist Market Share by Type in 2022 & 2028 Figure 14. United States Long Acting Beta Agonist Market Size by Type (2017-2028) & (US$ Million) Figure 15. United States Long Acting Beta Agonist Market Share by Type (2017-2028) Figure 16. Product Picture of Hospitals Figure 17. Product Picture of Clinics Figure 18. Product Picture of Ambulatory Surgical Center Figure 19. Product Picture of Others Figure 20. Global Long Acting Beta Agonist Market Share by Application in 2022 & 2028 Figure 21. Global Long Acting Beta Agonist Market Size by Application (2017-2028) & (US$ Million) Figure 22. Global Long Acting Beta Agonist Market Share by Application (2017-2028) Figure 23. United States Long Acting Beta Agonist Market Share by Application in 2022 & 2028 Figure 24. United States Long Acting Beta Agonist Market Size by Application (2017-2028) & (US$ Million) Figure 25. United States Long Acting Beta Agonist Market Share by Application (2017-2028) Figure 26. North America Long Acting Beta Agonist Market Size Growth Rate 2017-2028 (US$ Million) Figure 27. U.S. Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 28. Canada Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Europe Long Acting Beta Agonist Market Size Growth Rate 2017-2028 (US$ Million) Figure 30. Germany Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. France Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. U.K. Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. Italy Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Russia Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Asia-Pacific Long Acting Beta Agonist Market Size Growth Rate 2017-2028 (US$ Million) Figure 36. China Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Japan Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. South Korea Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. India Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. Australia Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Taiwan Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Indonesia Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Thailand Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Malaysia Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Philippines Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Latin America Long Acting Beta Agonist Market Size Growth Rate 2017-2028 (US$ Million) Figure 47. Mexico Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Brazil Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Argentina Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Middle East & Africa Long Acting Beta Agonist Market Size Growth Rate 2017-2028 (US$ Million) Figure 51. Turkey Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Saudi Arabia Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. U.A.E Long Acting Beta Agonist Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Sumitomo Dainippon Pharma Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 55. AstraZeneca Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 56. GlaxoSmithKline Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 57. Boehringer Ingelheim International Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 58. Mylan Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 59. Teva Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 60. Merck Revenue Growth Rate in Long Acting Beta Agonist Business (2017-2022) Figure 61. Bottom-up and Top-down Approaches for This Report Figure 62. Data Triangulation Figure 63. Key Executives Interviewed

Sumitomo Dainippon Pharma AstraZeneca GlaxoSmithKline Boehringer Ingelheim International Mylan Teva Merck